I would suggeset having a look at the auzbiz interview done with TO today. https://******.com.au/media/promising-results-for-adaltas-groundbreaking-drug-for-fibrotic-diseases?videoId=34776
Key part mentioned by TO at the end is the general agreement for IPF trials is around 40 mill US, with going up to 1B dependant on milestones. Forget the 1B part because that is years away but if we do get an agreement with that amount of funding, I would imagine a company with MC of 15M (current SP) that receives 60 mil (AUD) in funding would rerate quite hard.
Again, that's IF we get funding. Quite the make or break period coming up. Without funding there really isn't much on the horizon to increase market value but that's the risk of biotech shares.
Gonna be an interesting wait period. Unlike todays announcement which was televised on the release date, this agreement could drop at any moment. While I would imagine on the day of the announcement, it will run further, the instant bags will be made on open, so I would guess there will be some SP appreciation in time.
May be a few months of no money for holders but if the agreement does eventuate it would be worth the wait
1AD Price at posting:
2.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)